Literature DB >> 7729612

Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.

L D Monti1, G Lucignani, C Landoni, R M Moresco, P Piatti, I Stefani, G Pozza, F Fazio.   

Abstract

Myocardial and whole-body glucose metabolism was assessed in 19 insulin-dependent diabetes mellitus (IDDM) patients. A hyperglycemic clamp was performed 1) in the absence of insulin at free fatty acid (FFA) levels of 1.0 mmol/l (test 1); 2) in the absence of insulin at low FFA levels (0.1 mmol/l) by means of a lipid-lowering drug, acipimox (test 2); 3) during insulin infusion to achieve systemic levels of 400 pmol/l and FFA levels of 0.1 mmol/l (test 3); and 4) at the insulin levels of test 3 but increasing FFA to 1.0 mmol/l by means of heparin and intralipid infusion (test 4). Myocardial glucose uptake was measured by positron emission tomography (PET) and 2-[18F]fluoro-2-deoxy-D-glucose. Whole-body glucose uptake was measured in the four conditions by the glucose infusion rate during the PET scanning period. Myocardial glucose uptakes were 40.3 +/- 18.0, 395.5 +/- 139.6, 852.2 +/- 99.1, and 1,388.4 +/- 199.1 mumol.kg tissue-1.min-1 (mean +/- SD) and whole-body glucose uptakes were 10.1 +/- 2.3, 10.1 +/- 3.4, 42.8 +/- 5.8, and 30.5 +/- 5.6 mumol.kg body wt-1.min-1 during tests 1, 2, 3, and 4, respectively. Thus, in IDDM patients without coronary artery disease under the condition of hyperglycemia, an increase of myocardial glucose uptake was obtained either by lowering of FFA levels during hypoinsulinemia or by an increase in FFA levels during hyperinsulinemia. In both conditions no significant changes of whole-body glucose uptake were demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729612     DOI: 10.2337/diab.44.5.537

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

Review 1.  Imaging of myocardial fatty acid oxidation.

Authors:  Kieren J Mather; Timothy R DeGrado
Journal:  Biochim Biophys Acta       Date:  2016-02-27

Review 2.  Radionuclide imaging of myocardial metabolism.

Authors:  Linda R Peterson; Robert J Gropler
Journal:  Circ Cardiovasc Imaging       Date:  2010-03       Impact factor: 7.792

3.  Low-carbohydrate diet versus euglycemic hyperinsulinemic clamp for the assessment of myocardial viability with 18F-fluorodeoxyglucose-PET: a pilot study.

Authors:  José Soares; Filadelfo Rodrigues Filho; Marisa Izaki; Maria Clementina P Giorgi; Rosa M A Catapirra; Rubens Abe; Carmen G C M Vinagre; Giovanni G Cerri; José Cláudio Meneghetti
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-20       Impact factor: 2.357

4.  Acipimox does not augment thallium-201 redistribution in the fasting state.

Authors:  M G Gunning; G Clunie; S Yepes-Mora; S Eastick; S R Underwood; J Bomanji; P J Ell
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

5.  PET detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus.

Authors:  Pilar Herrero; Janet McGill; Donna S Lesniak; Carmen S Dence; Shalonda W Scott; Zulfia Kisrieva-Ware; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2008 Nov-Dec       Impact factor: 5.952

Review 6.  Recent advances in cardiac positron emission tomography in the clinical management of the cardiac patient.

Authors:  Robert J Gropler; Pablo Soto
Journal:  Curr Cardiol Rep       Date:  2004-01       Impact factor: 2.931

Review 7.  Translation of myocardial metabolic imaging concepts into the clinics.

Authors:  Adil Bashir; Robert J Gropler
Journal:  Cardiol Clin       Date:  2009-05       Impact factor: 2.213

Review 8.  The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity.

Authors:  Qutuba G Karwi; Qiuyu Sun; Gary D Lopaschuk
Journal:  Cells       Date:  2021-11-21       Impact factor: 6.600

9.  Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies.

Authors:  Roni Nielsen; Helene Nørrelund; Ulla Kampmann; Hans Erik Bøtker; Niels Møller; Henrik Wiggers
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.